What to Expect From AbbVie Inc. in 2018
In the words of the legendary James Brown, I feel good.
Early this year, I bought a position in AbbVie (NYSE: ABBV). The big pharma stock is on track for 2017 to be its best year ever. And I'm sitting on a nice gain of 57%, a little higher than AbbVie's year-to-date gain because of the timing of when I bought the stock.
Now that 2017 is drawing to an end, though, it's time to focus on the new year. Will AbbVie's success continue into 2018? Here's what I think investors should expect from the drugmaker next year.
Source: Fool.com
AbbVie Inc. Aktie
177,62 €
1,06 %
Überwältigendes Buy-Interesse für AbbVie Inc.: 33 Buy-Einschätzungen ohne eine einzige Sell-Einschätzung.
Ein positives, aber moderates Potenzial für AbbVie Inc. mit einem Kursziel von 180 € im Vergleich zu 177.62 €.
